Thursday, November 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 16, 2026

Coinbase Faces New Rules As DeFi And USDC Partnerships Reshape Outlook

View original at finance.yahoo.com
“Q1 2026 revenue of US$1.41b and a net loss of US$394.12m”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Coinbase Global is trading at $195.43

    60% confidence
  • Clearer U.S. digital asset rules and new stablecoin requirements could give large institutions more confidence to work with regulated venues rather than sit on the sidelines or rely on offshore platforms

    60% confidence
  • Tighter stablecoin reward rules may reduce the attractiveness of USDC hold-and-earn products, which matters for USDC economics

    60% confidence
  • Coinbase stock is down 26.7% over the past year

    60% confidence
  • Coinbase is leaning harder into being core infrastructure rather than just a spot trading platform via its DeFi and payment partnerships

    60% confidence
  • Moving USDC into more use cases and onchain venues could diversify how Coinbase earns fees and strengthen its position against rivals like Binance, Kraken and Robinhood that are also chasing institutional flows and crypto payments

    60% confidence
  • Coinbase Q1 2026 net loss was US$394.12 million

    60% confidence
  • Coinbase stock is down 17.4% year to date

    60% confidence
  • Coinbase Q1 2026 revenue was US$1.41 billion

    60% confidence
  • The Digital Asset Market Clarity Act has bipartisan support in the Senate Banking Committee

    60% confidence

Data points we hold from this source

Coinbase Global · stock price195.43 USD
Coinbase Global · net income-394.12 USD
Coinbase Global · stock return 1yr-26.7 percent
Coinbase Global · stock return ytd-17.4 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com